LONDON--(EON: Enhanced Online News)--The global neuropathy pain treatment market is projected to grow to USD 6,948.98 million by 2021, at a CAGR of close to 6% over the forecast period, according to Technavio’s latest report.
“APAC is projected to be the fastest-growing regional segment of the neuropathy pain treatment market, exhibiting a CAGR of over 7% through the forecast period. The rising adoption of these drugs and its generics will boost the market revenue generation”
In this report, Technavio covers the market outlook and growth prospects of the global neuropathy pain treatment market for 2017-2021. The market research report provides a detailed segmentation and analysis based on indication (diabetic neuropathy, chemotherapy-induced neuropathy pain, and postherpetic neuralgia) and drug class (calcium channel alpha 2-delta ligands, serotonin-norepinephrine reuptake inhibitors (SNRIs), TCAs, and opioid analgesics).
|Neuropathic pain is a complex, chronic pain that is accompanied by tissue and nerve fiber damage or injury. Currently, vendors in the neuropathy pain treatment market are focusing on the development of drugs for the effective treatment of diabetic neuropathy pain. This is drawing increased investments to the market, thereby driving its growth.|
Technavio’s research study segments the global neuropathy pain treatment market into the following regions:
Neuropathy pain treatment market in the Americas
“The Americas is the largest regional segment of the neuropathy pain medicine market, generating more than 48% of the overall revenue. The US is the largest contributor to the market, driven by the introduction of new drugs and treatment for new indications,” says Sapna Jha, a lead analyst at Technavio for central nervous system research.
Currently, there is a growing focus on developing drugs for diseases such as postherpetic neuralgia, which will propel the market growth over the forecast period. Vendors are also seeking to increase market penetration by adopting inorganic growth strategies to expand their expertise.
Request a sample report: http://www.technavio.com/request-a-sample?report=57092
Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.
Neuropathy pain treatment market in EMEA
The market for neuropathy treatment in EMEA is expected to be worth USD 2,167.39 million by 2021. The growing awareness and well-established healthcare infrastructure in Europe have led to the higher demand for neuropathic pain drugs, mainly for diabetic neuropathy. Countries such as the UK, Italy, Spain, Germany, and France are witnessing an increased uptake of drugs for the treatment of diabetic neuropathy, which is expected to fuel the market growth in EMEA. The increased adoption of low-cost generics in the Middle East and Africa will affect the market dynamics in EMEA.
Neuropathy pain treatment market in APAC
“APAC is projected to be the fastest-growing regional segment of the neuropathy pain treatment market, exhibiting a CAGR of over 7% through the forecast period. The rising adoption of these drugs and its generics will boost the market revenue generation,” says Sapna.
Patent expiries of key branded therapies such as Eli Lilly’s Cymbalta are creating new opportunities in untapped markets for generics. In addition, the market looks promising in this region due to an increasing number of the geriatric demographic and the large population pool, especially in India and China, are likely to drive the market growth.
The top vendors in the global neuropathy pain treatment market highlighted in the report are:
- Eli Lilly
- Endo International
Browse Related Reports:
- Global Myasthenia Gravis Drugs Market 2017-2021
- Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2017-2021
- Global Central Nervous System Disorders Therapeutics Market 2016-2020
Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like in-vitro diagnostics, infectious and rare diseases, and life science research tools. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.
Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.
Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, resellers, and end-users.
If you are interested in more information, please contact our media team at email@example.com.